Statin therapy and serum transaminases among a cohort of HCV-infected veterans

Digestive Diseases and Sciences

Volumn 55, Issue 1, 2010, Pages 190-195

  Henderson, Louise M ^a,b   Patel, Shital ^a   Giordano, Thomas P ^a,b   Green, Linda ^b   El Serag, Hashem B ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Hepatitis C virus; Statins; Transaminases; Veterans

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; MEVINOLIN; SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT;

ADULT; AGE DISTRIBUTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANALYSIS OF VARIANCE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRESCRIPTION; PRIORITY JOURNAL; RANK SUM TEST; RETROSPECTIVE STUDY; VETERAN; BLOOD; DRUG EFFECT; ENZYMOLOGY; LIVER; MIDDLE AGED; UNITED STATES;

ALANINE TRANSAMINASE; ANTICHOLESTEREMIC AGENTS; ASPARTATE AMINOTRANSFERASES; COHORT STUDIES; HEPATITIS C; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER; MALE; MIDDLE AGED; UNITED STATES; VETERANS;

EID: 74049088561     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-009-0959-1     Document Type: Article

References (25)

1. Kung HC, Hoyert DL, Xu JQ, et al. Deaths: final data for 2005. National vital statistics reports, vol 56, no 10. Hyattsville, MD: National Center for Health Statistics; 2008.
2. D Lloyd-Jones R Adams M Carnethos, et al. 2009 Heart disease and stroke statistics-2009 update: a report from the American Heart Association statistics committee and stroke statistics subcommittee Circulation 119 e1 e161 10.1161/CIRCULATIONAHA.108.843938
3. Centers for Disease Control and Prevention (CDC). State-specific cholesterol screening trends: United States, 1991-1999. MMWR. 2000;49:750-5.
4. AM Gotto 2002 Statins: powerful drugs for lowering cholesterol Circulation 105 1514 1516 10.1161/01.CIR.0000014245.25136.D2 11927509 (Pubitemid 34297619)
5. RC Pasternak SC Smith CN Bairey-Merz, et al. 2002 ACC/AHA/NHLBI clinical advisory on the use and safety of statins JACC 3 567 572
6. National Cholesterol Education Program (NCEP) 2002 Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report Circulation 06 3143 3421
7. S De Denus SA Spinler K Miller, et al. 2004 Statins and liver toxicity: a meta-analysis Pharmacotherapy 24 584 591 10.1592/phco.24.6.584.34738 15162892 (Pubitemid 38585952)
8. S Khorashadi NK Hasson RC Cheung 2006 Incidence of statin hepatotoxicity in patients with Hepatitis C Clin Gastroenterol Hepatol 4 7 902 907 10.1016/j.cgh.2006.03.014 1:CAS:528:DC%2BD28XotFars7w%3D 16697272 (Pubitemid 43994535)
9. K Gibson JP Rindone 2005 Experience with statin use in patients with chronic hepatitis C infection Am J Cardiol 96 9 1278 1279 10.1016/j.amjcard. 2005.06.071 1:CAS:528:DC%2BD2MXhtFKmtLnE 16253597 (Pubitemid 41505408)
10. M Segarra-Newnham D Parra EM Martin-Cooper 2007 Effectiveness and hepatoxicity of statins in men seropositive for hepatitis C virus Pharmacotherapy 27 6 845 851 10.1592/phco.27.6.845 1:CAS:528: DC%2BD2sXntVyltbY%3D 17542767 (Pubitemid 46849428)
11. DE Cohen FA Anania N Chalasani 2006 An assessment of statin safety by hepatologists Am J Cardiol 97 suppl 77C 81C 10.1016/j.amjcard.2005.12.014 1:CAS:528:DC%2BD28XkvF2gsrg%3D 16581333
12. J Ye C Wang R Sumpter Jr, et al. 2003 Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation Proc Natl Acad Sci USA 100 26 15865 15870 10.1073/pnas.2237238100 1:CAS:528: DC%2BD2cXhtVClug%3D%3D 14668447 (Pubitemid 38021081)
13. SB Kapadia FV Chisari 2005 HCV RNA replication is regulated by host geranylgeranylation and fatty acids Proc Natl Acad Sci USA 7 2561 2566 10.1073/pnas.0409834102 (Pubitemid 40279416)
14. M Ikeda K Abe M Yamada, et al. 2006 Different anti-HCV profiles of statins and their potential for combination therapy with interferon Hepatology 44 1 117 125 10.1002/hep.21232 1:CAS:528:DC%2BD28XnsFWjtL4%3D 16799963 (Pubitemid 44049145)
15. T Bader J Fazili M Madhoun, et al. 2008 Fluvastatin inhibits hepatitis C replication in humans Am J Gastroenterol 103 6 1383 1389 10.1111/j.1572-0241. 2008.01876.x 1:CAS:528:DC%2BD1cXos1Wrt7c%3D 18410471 (Pubitemid 351813920)
16. AL Avins MM Manos L Ackerson, et al. 2008 Hepatic effects of lovastatin exposure in patients with liver disease: a retrospective cohort study Drug Saf 31 4 325 334 10.2165/00002018-200831040-00006 18366243
17. Wackerly DD, Mendenhall W III, Scheaffer RL. Mathematical statistics with applications. Belmont, CA: Wadsworth Publishing Company, Duxbury Press; 1996.
18. SS Bhardwaj N Chalasani 2007 Lipid-lowering agents that cause drug-induced hepatotoxicity Clin Liver Dis 11 597 613 10.1016/j.cld.2007.06.010 17723922 (Pubitemid 47304463)
19. MD Onofrei KL Butler DC Fuke, et al. 2008 Safety of statin therapy in patients with preexisting liver disease Pharmacotherapy 28 4 522 529 10.1592/phco.28.4.522 1:CAS:528:DC%2BD1cXkvFWrt7k%3D 18363535
20. N Chalasani Aljadhey J Kesterson, et al. 2004 Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity Gastroenterology 126 1287 1292 10.1053/j.gastro.2004.02.015 1:CAS:528:DC%2BD2cXksF2qtLw%3D 15131789 (Pubitemid 38552793)
21. JH Lewis ME Mortensen S Zweig, et al. 2007 Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial Hepatology 46 1453 1463 10.1002/hep.21848 1:CAS:528:DC%2BD2sXhtlOiu7bM 17668878 (Pubitemid 350155527)
22. A Mallat AM Preaux S Blazejewski, et al. 1994 Effect of simvastation, an inhibitor of hydroxyl-methylglutaryl coenzyme A reductase, on the growth of human lto cells Hepatology 20 6 1589 1594 10.1002/hep.1840200631 1:CAS:528:DyaK2MXivFWgtrc%3D 7982659 (Pubitemid 24359074)
23. K Rombouts E Kisanga K Hellemans, et al. 2003 Effect of HMG-CoA reductase inhibitors on proliferation and protein synthesis by rat hepatic stellate cells J Hepatol 38 564 572 10.1016/S0168-8278(03)00051-5 1:CAS:528: DC%2BD3sXjtFertrY%3D 12713866 (Pubitemid 36560640)
24. C Wang M Gale B Keller, et al. 2005 Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication Mol Cell 18 425 434 10.1016/j.molcel.2005.04.004 1:CAS:528:DC%2BD2MXkslaqu7g%3D 15893726 (Pubitemid 40704757)
25. AS Lok JE Everhart RT Chung HY Kim GT Everson JC Hoefs JK Greenson RK Sterling KL Lindsay WM Lee AM Di Bisceglie HL Bonkovsky MG Ghany C Morishima HALT-C Trial Group 2009 Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial Hepatology 49 1828 1837 10.1002/hep.22865 1:CAS:528:DC%2BD1MXotVCmtLs%3D 19291787